B lymphocyte-restricted transcription of immunoglobulin heavy-chain (IgH) genes is specified by elements within the variable region (Va) promoter and the intronic enhancer (EIX). The gene encoding a protein that binds a VH promoter proximal site necessary for induced ix-heavy-chain transcription has been cloned. This B-cell specific protein, termed Bright (B cell regulator of IgH transcription), is found in both soluble and matrix insoluble nuclear fractions. Bright binds the minor groove of a restricted ATC sequence that is sufficient for nuclear matrix association. This sequence motif is present in previously described matrix-associating regions (MARs) proximal to the promoter and flanking EIX. Bright can activate Ela-driven transcription by binding these sites, but only when they occur in their natural context and in cell lines permissive for E~ activity. To bind DNA, Bright requires a novel tetramerization domain and a previously undescribed domain that shares identity with several proteins, including SWI1, a component of the SWI/SNF complex.
berger Scheuermann and Chen 1989; Genetta et al. 1994 ). In one model, non-B cell factors would bind the MARs and limit core accessibility (Scheuermann 1991; Dickinson et al. 1992) .
However, recent work suggests that these MARs facilitate enhancer function in B cells by impacting chromatin structure. In virus-transformed pre-B cells, transgenic EIX constructs required both flanking MAR sequences for DNase I hypersensitivity and high-level transcription (Jenuwein et al. 1993) . A follow-up study in vivo demonstrated that although the core was necessary for locus transcription, IgH transgenes lacking the MARs lost both position-independent high level expression and extended domain DNase I hypersensitivity (Forrester et al. 1994) . Thus, the Ep, core in concert with the MARs appears to function as a locus control region (LCR) similar to the LCR of the human [3-globin gene (Forrester et al. 1987; larman and Higgs 1988; Talbot et al. 1989} .
We have developed a system in which a B cell line (BCg3R), transfected with sequences encoding the heavy and light chains of a phosphorylcholine-specific antibody, responds to a combination of antigen plus interleukin (IC) 5 (Webb et al. 1989) . The response, an increase in the amount of ix-heavy-chain transcription, resembles that seen when normal B cells are exposed to these stimuli (Alderson et al. 1987; Swain et al. 1988) . Subsequent experiments correlated this transcriptional response with induced binding of a B-cell specific complex upstream of the S 107 variable region (VH) promoter, at -125 to -251 (Tx125) and -424 to -574 (Bfl50) from the transcriptional start (Webb et al. 1991a) . Sequence analysis revealed both Bfl50 and Tx125 to be AT rich and the entire region was shown to function as a MAR (Webb et al. 1991b) . Using a Bfl50 site concatamer we have cloned a eDNA encoding this B cell-specific protein, termed Bright. Bright has two newly described domains that confer multimerization and DNA binding. We will show that Bright binds the minor groove of a consensus MAR sequence proximal to the S107 V H promoter and flanking EIX, and that it trans-activates gene expression driven by EIX. These observations provide the first evidence for transcriptional regulation by a MARbinding protein.
Results
The rearranged S107 IgH locus contains three previously defined MARs (Cockerill et al. 1987; Webb et al. 1991b) , and several protein-binding sites have been localized in these regions (Fig. 1) . A mature B cell complex induced by antigen plus IL-5 binds Bfl50 and Tx125 in the promoter MAR (Webb et al. 1991a ). NF-IXNR, a complex absent in mature B cells, binds four sites (P1, P2, P3, and P4) in the MARs flanking EIX (Scheuermann and Chen 1989) . SATB1, a T-cell protein, binds sites I-VI with notable overlap at the P2, P3, and P4 sites in regions of high base-unpairing potential (Kohwi-Shigematsu and Kowhi 1990; Dickinson et al. 1992} . We have found that Bfl50, Tx125, and P2 all cross-compete for binding to both the mature B cell factor and NF-~NR (B. Fishel and C. Das, unpubl.).
Cloning of Bright
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Bright expression is lineage and developmental stage restricted
Bright's expression pattern was verified by detection of both mRNA and protein from transformed lymphocyte lines. In Figure 4A , a Northern blot with 32p-labeled Bright eDNA detects a 5-kb message in poly(A} + RNA (odd-numbered lanes). This message accumulates in mature B cells but not in pre-B or T cell lines. These results are consistent with the full-length eDNA size and the expression pattern predicted from the mobility-shift experiments. Smaller transcripts corresponding to utilization of the upstream poly(A) site have not been detected. A ribonucIease protection assay, shown in Figure 4B ification may be i m p o r t a n t for changes in binding activity.
Bright binds in the minor groove and recognizes A T / A T C sequences flanking the promoter and EIx core
The T cell protein SATB1 binds AT-rich MAR sequences, characterized by all A's, T's, and C's on one strand {ATC sequence), by recognizing a specific sugarphosphate structure in the m i n o r groove (Dickinson et al. 1992) . Knowing that Bright bound MAR sites proximal to the promoter {Bfl50, Tx125) and 5' of the en- Monomer hancer (NF-v.NR, P2; and SATB1, II}, we suspected it might also bind in the minor groove. Distamycin A binds the minor groove of DNA and inhibits several MARprotein interactions in vitro, including those of SATB1 (Adachi et al. 1989; Kas et al. 1989; Dickinson et al. 1992) . In Figure 5 , distamycin A completely inhibits Bright binding to a Tx125 probe at ~>5 mM (lanes 3-7). The protein QRF-1 contains a forkhead domain and binds Tx125 at a different site as both a monomer and dimer, primarily through major groove contacts (Clark et al. 1993; Li and Tucker 1993) . Distamycin A, even at 100 mM, has little effect on QRF-1 dimer binding and is unable to block monomer binding (Fig. 5, lanes 9-13) . These results show clearly that Bright requires a minor groove interaction to bind its target sequences. Native binding sites for Bright in the E~ MARs were identified with mobility-shift competitions. In Figure  6A , the three IgH locus MARs inhibit Bright binding at 30-fold molar excess (lanes 2,3,5). This inhibition is lost when the NF-~NR sites are deleted from the 5' (AP1, P2) and 3' (AP3, P4) E~ MARs (lanes 4,6). We then determined Bright's affinity for these sites. In Figure 6B , Bright binds the E~ 5' MAR (lane 1), and self-inhibition (lanes 2-4) depends solely on P2, as the aXPl fragment inhibits binding completely (lanes 8-10), whereas the AP2 fragment does not (lanes 5-7). In Figure 6C , Bright binds the EV. 3' MAR (lane 1), and self-inhibition (lanes 2-4) depends primarily on P3 (AP4; lanes 5-7) and to a lesser extent on P4 (AP3; lanes 8-10). In Figure 6D , mobility shift with labeled Ap fragments demonstrates further Bright's affinity for these sites as P3 (lanes 7-9}, ~>P2 (lanes 4--6), >P4 (lanes 10--12), > > > P 1 (lanes 1-3) .
Oligonucleotide competitions were used to localize binding targets within the promoter fragments Bf 150 and Tx125 and the enhancer fragment P2. The oligonucleotide sequences are shown in Figure 6E (BF, TX, and P2). In Figure 6A , concatamers of these oligonucleotides inhibit Bright binding at 10-fold molar excess (lanes 7,8,10) , whereas concatamers of a low-affinity oligonucleotide TXD and a mutated P2 oligonucleotide do not (lanes 9,11). Alignment of tested sequences is shown in Figure 6E . Those with high affinity {P2, P3, BF, TX) contain three features: (11 a core hexamer of AATTAA or AATAAA in an AT/ATC run defined by (2) >113 bp of ATC sequence that contains (3) a second AT dimer ~ 6 bp from the hexamer. Of note, the SATB1 footprint falls on top of the AT dimers and extends into the core hex o amer at the P2 and P3 sites (Fig. 6E ).
Bright binds A T / A T C sequences containing a core hexamer
To further characterize Bright's recognition sequence, we performed a series of cyclic amplification and selection of target (CASTing) experiments (Funk and Wright 1992!. Twenty-seven unique sequences were isolated by the CASTing protocol, and their relevant portions are aligned in Figure 7A . In all 27 isolates, the full sequence was >70% AT rich and contained at least one hexamer consisting of AATTAA, AATAAA, or GATTAA. In 24 isolates, all three features suggested by native site alignment were present. Isolates not fulfilling all three criteria are shown below the consensus in Figure 7A ; of these, two had degenerate core hexamers in the AT/ATC run and only one failed to have an AT/ATC run/>13 bp.
To confirm the binding consensus, we determined Bright's affinity for P2 oligonucleotide mutations concatamerized to three repeats in a mobility-shift assay. The mutated oligonucleotides are aligned in Figure 7B . As shown in Figure 7C , a 2-or 3-base change in the core hexamer (mutations 1,3,4) has the greatest impact on binding. A single-base change in the core (mutation 5) has much less effect. When a single-base core change is coupled with loss of the AT dimer (mutation 2) or shortening the AT/ATC run <13 bp (mutation 6), binding activity is affected severely. Shortening the A T / A T C run to 15 bp (mutation 10) has little effect, but shortening it to 12 bp tmutation 8)affects binding dramatically. Mutations 7 and 9 add an additional AT dimer within 6 bases of the core, and as expected, this change augments binding compared to the wild-type concatamer [wtigl] . These results support the binding consensus suggested P2 site oligo
The IgH MARs are bound by Bright Figure 6 . Bright binds specific MAR sites proximal to the promoter and flanking EFt.
{A-D)
EMSA with 10 ng Bright in vitro translate, labeled probe, and cold competitor fragments preincubated at the indicated molar excess or titrated at 10-, 20-, and 30-fold excess. MAR fragments are described in Fig. 1 by native site alignment. Thus Bright, like SATB1, requires an ATC sequence for binding; however, Bright also requires a m i n i m u m ATC length of 13 bp, a core consensus hexamer, and two closely spaced AT dimers.
The A T / A T C sequence bound by Bright is a matrix attachment site
The A T C sequence bound by SATB1 has been shown to be present in MARs from different species and may represent a consensus recognition site for nuclear matrix association (Dickinson et al. 1992) . However, it is unclear w h e t h e r additional features are required. We took a concatamerized wild-type P2 oligonucleotide [P2-sitecsl] and tested its affinity for isolated nuclear matrix as compared to concatamers of two m u t a t e d P2 oligonucleotides: one that bound Bright strongly [mutation 10: P2-mut.10t41] and one that bound Bright weakly [ m u t a t i o n 2: P2-mut.21sl] (see Fig. 7B , C}. In Figure 8A , m u t a t i o n 2 (lanes 1,2) can be seen to partition almost entirely in the s u p e m a t a n t fraction (Sn), indicating poor affinity for the nuclear matrix, whereas m u t a t i o n 10 (lanes 3,4) and P2 wild type (lanes 5,6) partition p r e d o m i n a t e l y in the matrix-bound fraction (B). As shown in Figure 7B , all three oligonucleotides have ATC runs I>13 bp; however, mutation 2 has lost an AT dimer. In Figure 8B , the addition of cold P2 wild type at 100-fold molar excess (lanes 3,4) significantly inhibits matrix association of labeled MAR fragments, whereas cold m u t a t i o n 2 at 100-fold molar excess (lanes 5,6)has no effect.
A brief inspection of all six SATB1 sites in the El* MARs (Dickinson et al. 1992 ) and the two Bright sites in the S107 5' promoter MAR (see Fig. 6E ) reveals the presence of at least two closely spaced AT dimers w i t h i n an ATC run. This observation, coupled with the above results, suggests that the A T / A T C sequence, in addition to being a requirement for Bright binding, defines a consensus MAR recognition site.
Bright trans-activates only in the context of an active wild-type IgH enhancer
In stable transfections, the promoter proximal site Tx125 was shown to be necessary for inducible heavychain transcription (Webb et al. 1991a To ensure that trans-activation was specific for Bright binding, we tested a CAT vector with the AEt~ fragment cloned upstream of the tk promoter. All of the Bright and NF-i.tNR-binding sites are deleted from this fragment (see Fig. 11 . Compared to EI~, AEt~ was still an efficient enhancer and in control experiments it increased CAT expression 2.7-fold in EL4 and 1.5-fold in J558. However, in the absence of its binding sites Bright could not trans o activate this vector (Table 1) .
Previous studies demonstrated that EIJ. is active in J558, M12.4, and EL4, but not in the T cell line BW5147 ( 3,4) , whereas mutation 2 does not (lanes 5.61.
(B) MAR-binding assay as above with labeled E~t MAR fragments (left) and cold competitor fragments (reverse image above lanes added). P2 wild type inhibits Eg MAR binding (lanes
anticipated, background levels of Ep~-CAT activity that are unaffected by Bright cotransfection were observed in BW5147 cells (Table 1) . Thus, Bright-directed trans-activation requires the presence of its binding sites in the context of an active enhancer element.
Bright contains a previously undescribed domain necessary for DNA binding
A search of the PIR data base yielded a limited region of homology among Bright and two human proteins, modulator regulatory factors (MRF/ 1 and 2A (B. Whitson, T.H. Huang, B.W. Merrills, T. Asai, and K. Itakura, in prep.l. These proteins share an identity of 30%-35% (Fig. 9) , similar to that seen among helix-loop-helix proteins of different families. Two other proteins, the yeast transcription factor SWI1/Adr6 (Taguchi and Young 1987; Peterson and Herskowitz 1992) and human retinoblastoma-binding protein RBP1 (Fattaey et al. 1993) , also share this region of identity (Fig. 9) . The most impressive homology is with the Drosophila protein, Dead ringer (dri) (S. Gregory, R.D. Kortschak, B. Kalionis, and R. Saint, in prep.). The region of homology between Bright and dri stretches over 132 residues and is 78% identical (Fig. 9) . With conservative replacements taken into account, the degree of similarity rises to 87%. This remarkable conservation is comparable to that seen in homeo domains but extends over a larger region (Scott et al. 1989) .
MRF1, MRF2A, and dri all bind AT-rich DNA; therefore, we tested the importance of the conserved domain for Bright binding. A series of cDNA deletion constructs {Fig. 10A) were translated in vitro and assayed for binding activity in mobility-shift experiments. Figure 10B demonstrates that 5' deletions extended just amino-terminal of the conserved domain in constructs 1 (AIM 78), 2 (A1-215), and 3 (A61-224) do not affect binding activity, whereas deletions into the conserved domain do in constructs 4 (A61-244) and 6 (A1-247). A small carboxyterminal deletion in construct 10 (A562-601) has no effect, although more extensive deletions in constructs 8 (A381-6011 and 9 (A489-601), despite being well outside the conserved domain, do affect binding (Fig. 10B) . Because it seemed unlikely that the DNA-binding domain spanned such a large nonconserved region of the protein, we reasoned that some portion of the carboxyl terminus was required for homotypic interactions.
Bright binds DNA as a tetramer
Several experiments were performed to detect higher order structures in the Bright complex. Nonreducing gels and Sephadex gel filtration of in vitro-translated protein demonstrated high molecular weight complexes corresponding to a Bright homo-tetramer (data not shown). To analyze these complexes, a full-length Bright construct (F.L.) was translated separately or cotranslated with a deletion construct before DNA binding and mobilityshift assay (Fig. 10C) . Separate translation and mixing of F.L. and construct 2 (A1-215) produces two complexes that correspond to those seen with each construct by itself (Fig. 10C ). When these two constructs are cotranslated (*), five binding complexes are resolved, corresponding to all combinations of long-short proteins in the tetramer (Fig. 10C) . Thus, four copies of the protein exist in the DNA-binding complex. It also appears that formation of the tetramer occurs with assembly of the protein, in the absence of DNA, and is strong enough not to allow "breathing." We mapped the tetramer domain with further deletions. Construct 10 (A562-601) binds DNA with full activity (Fig. 10B /. Construct 9 (A489-601/has no activity either mixed or cotranslated (*) with F.L. (Fig. 10C) . Construct 5 (A61-244/562-601/has a 20-amino-acid aminoterminal deletion in the conserved domain and does not bind DNA when translated separately from F.L. (Fig.  10C) . However, when it is cotranslated (*} with F.L. a rescue phenomenon, with the formation of three lower complexes, is observed (Fig. 10C) . Apparently, a small deletion in the conserved domain can be complemented by functional protein. Construct 7 (A61-266) has a larger conserved domain deletion, does not bind DNA on its own, and does not form intermediate complexes when cotranslated (*) with F.L. (Fig. 10C ). There is a reproducible loss of intensity from the full-length complex (~50%), suggesting that functional protein is being sequestered with A61-266 protein into nonfunctional tettamers. This provides further evidence that the conserved domain is a required component for the tetramer to bind DNA. To verify these interactions, we performed immunoprecipitations with hemaglutinin (HA}-tagged fulllength Bright. The HA-tagged version was cotranslated with Bright deletion constructs and precipitated with anti-HA monoclonal bound to protein G--agarose. Products that bind DNA, 10 (&562-601) and 2 (&1-2151, were coprecipitated (Fig. 10D ). In addition, products 5 (.~61-244/562-601), 6 (A1-247), and 7 (2161-266) that have deletions in the DNA-binding domain, but intact carboxyterminal ends, were also coprecipitated (Fig. 10D} . However, products 8 (A381-601) and 9 (A489-6011 that lack the region between amino acids 489 and 561 were not coprecipitated with HA-tagged Bright (Fig. 10D) . This region, then, is essential for m u h i m e r i z a t i o n and ultimately for DNA binding.
The trans-activation domain lies between the boundaries of the DNA-binding and multimerization domains
Deletion constructs that still maintained DNA-binding activity were tested for their ability to trans-activate the E~x-CAT construct. Proteins with amino-terminal deletions up to the DNA-binding domain remained efficient trans-activators (summarized in Fig. 10A} . Thus, the large acidic region, characteristic of several trans-activation domains, is not important in this assay system. The carboxy-terminal A562-601 deletion also had full transactivation potential, indicating that the trans-activation domain lies between the amino terminus of the binding domain and the carboxyl terminus of the tetramer domain.
D i s c u s s i o n
Studies by Webb et al. (199 la) implicated a DNA-binding complex in the up-regulation of IgH expression after stimulation of a responsive B cell line. This report describes the cloning and characterization of this protein, called Bright. We have shown that Bright is restricted to mature stage B cells, binds MAR sequences flanking the Figure 9 . Six-member alignment of a conserved region defines a new DNAbinding domain family. Solid residues are identical to Bright, and shaded boxes indicate conservative substitutions. Numbers indicate amino acid position. Robert Saint {University of Adelaide, Australia) kindly provided the dri sequence. All other sequences were retrieved from the PIR data base or from published data MRF1 (accession nos. $27962}; MRF2A ($27963); SWI1/Adr6 (S05728); RBP1 (Fattaey et al. 1993) . Both MRF1 and MRF2A were partial cDNAs with incomplete open reading frames. ~381-6ei (8) a489 681 (9) a562~6~I ( 
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(2) (6) (8) E~ core, and activates transcription driven by E~. This protein forms a homo-tetramer and binds DNA with a newly described domain that is conserved among several family members including SWI1. These observations suggest a role for Bright in IgH gene expression.
Bright and NF-laNR bind similar IgH MAR sequences;
Cold Spring Harbor Laboratory Press on October 19, 2017 -Published by genesdev.cshlp.org Downloaded from however, their mobility-shift complexes show a reciprocal lymphoid expression pattern. Bright mRNA and protein, although, absent from pre-B and T cell lines, are present in mature B-cell lines. The failure to detect Bright message in resting splenocytes undoubtedly reflects its restriction to activated B cell stages. Activated B cells respond to antigen and T cell signals, and this ability has been modeled in the BCg3R cell line {Webb et al. 1989). The transcriptional response of these cells to antigen plus IL-5 was shown to require a promoter proximal Bright-binding site and to parallel augmented Bright complex formation on mobility-shift assay (Webb et al. 1991a) . As suggested by Western blot data, induction of Bright binding may involve some form of post-translational modification. However, Bright's role in relation to steady-state versus stimulated immunoglobulin expression is not known.
Bright binds the minor groove of MAR sequences located upstream of the IgH S 107 variable region promoter (Bfl50, Tx125) and flanking the intronic enhancer E~. (P2, P3, and P4). Several of these sites also bind NF-~NR and SATB1, and contain two essential features: (1) an ATC run/> 13 bp, and (2) two closely spaced AT dimers. Although Dickinson et al. (1992) first demonstrated the importance of the ATC sequence for matrix association, we have shown that the AT dimer feature is also necessary. This type of ATC sequence (AT/ATC) defines a consensus MAR-binding site and is recognized by Bright, SATB1, and the matrix-associated protein Nucleolin (Dickinson et al. 1992; Dickinson and Kohwi-Shigematsu 1995) . Bright binds AT/ATC sequences but only if a core recognition hexamer (AATTAA, AATAAA, or GATTAA) is also present. Bright does not tolerate loss of the AT dimer (mutation 2) or the ATC run (mutation 8}, but will tolerate limited degeneracy in the hexamer as evidenced by the P4 site (AATTAT) and mutation 5 {AATTCA). Thus, the core hexamer targets Bright to specific matrix attachment sites.
We demonstrated that Bright trans-activates CAT expression vectors in a transient cotransfection system. This trans-activation was dependent on enhancer function and correlated with E~. activity in the cell lines tested. It was also specific for DNA binding, as deletion of Bright's binding sites (P2, P3, and P4) from the MARs flanking the E~ core rendered the AE~-CAT vector impervious to activation after Bright cotransfection. However, in control experiments AE~-CAT was more active than E~.-CAT in the T cell line EL-4 and the plasma cell line J558. The deleted sites in AE~-CAT are also bound by putative T cell repressors NF-~NR and SATB 1, giving a rationale for increased expression from this vector in EL-4. The situation for J558 is less clear, but the implication is that these sites also carry a net negative input on enhancer function in this cell line. Whether this results from pure DNA topological constraints or from factor binding in addition to Bright is not known. The deleted sites contain the AT/ATC sequence motif that is recognized by other MAR proteins; therefore, it seems likely that these regions would bind multiple factors. If the MARs act by affecting DNA topology, then proteins such as histones, binding the MAR, could mediate repression at some level of Bright expression. In this scenario, removal of the MAR sites would relieve repression, as would Bright overexpression by affecting the stoichiometry of factor binding. The same effect is not seen in M 12.4 cells. However, the low level of enhancer activity makes differences between E~ and AE~ less meaningful. Clearly, Bright does not act alone, but exactly how it activates E~-driven transcription will require further study.
Bright, like other MAR-binding proteins, exists both free in the nucleus and in association with the nuclear matrix, but remains distinct at the amino acid level from these proteins, including SATB1, which binds a nearly identical sequence (Adachi et al. 1989; Hofmann et al. 1989; Izaurralde et al. 1989; von Kries et al. 1991; Luderus et al. 1992; Romig et al. 1992; Tsutsui et al. 1993; Zhao et al. 1993; Nakagomi et al. 1994; Dickinson and Kohwi-Shigematsu 1995) . Bright does share a domain (amino acids 226-3601 with the proteins dri, RBP1, SWI1, MRF1, and MRF2A, although the greatest region of homology among all family members is limited to amino acids 249-331. Bright protein with a deletion up to amino acid 246 does not bind DNA but can be complemented by the full domain into a functional binding complex. This suggests that important binding structures reside within the limited domain. Although sitespecific DNA binding has not been reported for SWI1 or RBP1, the MRF and dri proteins do bind specific AT-rich sequences lB. Whitson, T.H. Huang, B.W. Merrills, T. Asai, and K. Itakura, in prep.; S. Gregory, R. D. Kortschak, B. Kalionis, and R. Saint, in prep.). We and the groups cloning the MRF and dri genes have named this the ARID domain (AT-rich interaction domain) and a discussion of its secondary structure will be presented elsewhere. By showing that this domain is necessary for binding activity, we have defined a new family of DNAbinding proteins.
We have identified one additional functional domain in Bright, a tetramer domain spanning amino acids 489-561. DNA binding was shown to require four molecules of Bright. However, DNA binding was not necessary for tetramer formation, as deletion constructs devoid of binding activity were able to multimerize if they contained the tetramer domain. There are no obvious structural motifs in this domain, although the amino-terminal half (amino acids 489-527) is rich in polar residues, which often mediate homotypic interactions.
Our studies and experiments by Taguchi and Young (19871, demonstrating regulation of the ADHII yeast gene by SWI1 reveal that proteins containing an ARID domain can mediate transcriptional activation. The SWI/SNF complexes containing SWI1 act as general transcriptional activators in both yeast and humans by altering chromatin structure (Peterson and Herskowitz 1992; Imbalzano et al. 1994; Kwon et al. 1994) . Bright is a MAR-binding protein, and it has been suggested that the ability of MARs to regulate transcriptional domains may relate to changes in chromatin structure effected by factors that bind them Zhao et al. 19931 .
Studies by Forrester et al. (1994) indicate that the IgH locus becomes remodeled or DNase I hypersensitive at the pre-B cell stage and that the Eia MARs are necessary for this event. The B-globin LCR also demonstrates remodeling before active domain transcription {Jimenez et al. 1992). Interestingly, in several genes, transcription factor access to core enhancer elements seems to occur even before these early remodeling events (Jenuwein et al. 1993; Aronow et al. 1995) . This suggests that additional topological changes or factors are required to activate transcription. The expression pattern, binding site location, and trans-activation potential of Bright put it in a position to fulfill this role. Thus, as B cells differentiate and respond to cytokine and antigen signals, Bright could affect structural chromatin changes through the MARs that activate Eia and drive IgH transcription.
There is no doubt that regulation of immunoglobulin transcription is complex. The growing numbers of factors that bind within the IgH intronic enhancer clearly work together to sustain high level gene expression in B lymphocytes. Although the maintenance of tissue restriction is still an interesting puzzle, the studies described here offer a Bright new path to follow.
Materials and methods

DNA probes and fragments
The S107 5' MAR, Bfl50, and Tx125 fragments have been described (Webb et al. 1991a ). Scheuermann and Chen {1989) described the 992-bp XbaI-XbaI murine intronic enhancer (E~) fragment and the location of the NF-~NR sites (P1 nucleotides 176-200, P2 nucleotides 285-333, P3 nucleotides 732-753, P4 nucleotides 791-826). The 5' and 3' E~ MARs consisted of a 381-bp XbaI-PstI fragment and a 309-bp EcoRI-XbaI fragment, respectively. The AE~t and AP1-AP4 constructs were made by sequential digestion and religation after insertion of the following restriction sites into the 992-bp E~ fragment with the MutaGene Mutagenesis Kit (Bio-Rad, Richmond, CA}: SpeI at positions 162 and 203, BglII at positions 277 and 341, XhoI at positions 697 and 759, and EagI at positions 782 and 825. Concatamers were constructed from annealed synthesized oligonucleotides (Applied Biosystems Inc., Foster City, CA) by blunt end or complimentary end ligation, electrophoretic separation of the ligation reaction, gel elution of the appropriate band size, and cloned into Bluescript vectors (Sambrook et al. 1989J . When referred to in figures and text n =number of concatamerized repeats.
Library screening and clone isolation
An IL-2-and IL-5-stimulated BCL1 KZap cDNA library, provided by Mark Davis (Turner et al. 1994) , was screened by the method of Singh et al. (1988) . Briefly, 5x 104 phage plaques were grown at 42°C until visible with filter overlays placed at 37°C overnight. Wet filters were blocked for 1 hr in buffer C [50 mM KC1, 20 mM HEPES, 0.5 mM MgC12, 0.5% Tween 20 (vol/vol), 0.05% NP-40 (vol/vol)(pH 7.9)] plus 5% (wt/vol) dry milk, washed, and incubated at 4°C overnight in buffer C plus 0.25% dry milk (wt/vol), 10 ~g/ml of sheared salmon sperm DNA, 2 ~g/ml of poly [d(I-C)] and 2x 106 cpm/ml of 32p-end-labeled BF site oligonucleotide multimerized to seven repeats. Filters were washed, dried, and exposed to radiographs overnight at -80°C with intensifying screens. Plaques that bound labeled probe were picked and purified to homogeneity. The library was rescreened by hybridization with labeled cDNA as described by Kaplan et al. (1993) . Isolated clones were converted to doublestrand plasmids by Stratagene's in vivo excision protocol (Stratagene Cloning Systems, LaJolla, CA) and sequenced on both strands with an automated fluorescent-tagged sequencing system (Applied Biosystems).
In vitro translation and transfection vectors
Bright cDNA constructs were cloned into the pBK-cytomegalovirus iCMV) plasmid (Statagene) and used for protein expression in the transfection and mobility-shift experiments. The full-length construct spanned nucleotides 268-2320 and was cloned into the XhoI site of pBK-CMV in both sense and antisense orientations. Translation of this construct initiates off of the second in-frame methionine at amino acid 7. Deletion constructs were made through a series of restriction site digests, polymerase chain reaction (PCR), and vector religation of the full-length construct. All constructs were sequenced to confirm proper orientation and in-frame alignment. In vitro transcription (T~ polymerase) and translation was performed with the TNT-coupled reticulocyte lysate system (Promega Corp, Madison, WI). Synthesized products were analyzed by gel electrophoresis to confirm correct expression size.
Electrophoretic mobility-shift assay
Nuclear extract isolation (Dignam et al. 1983 ) and IL-5 plus antigen induction {Webb et al. 1991a) of the BCg3R-ld cell line have been described. The electrophoretic mobility-shift assay (EMSA) was performed as described by Webb et al. (1991a) . Binding reactions consisted of 0.5-2 ~g of nuclear extract or 10 ng of cold in vitro cDNA translation reaction {1-3 ~zl for single construct and 3 ~1 for cotranslated consructs), 1 ~g of poly d(I-C} and DNA probes end labeled (Sambrook et al. 1989 ) to a sp. act. of 105 cpm/ng with [32p]dATP (ICN, Costa Mesa, CA), with modifications to buffer D [20 mM HEPES (pH 7.9), 20% glycerol ivol/voll, 50 mM KC1, 1% Tween 20 {vol/vol), 0.2 mM EDTA, 5 mM phenylmethylsulfonyl fluoride). Cold competitor fragments were allowed to bind for 5 min at 37°C before addition of labeled probe.
RNA analysis
Total RNA was isolated from cell lines and frozen mouse tissues with guanidinium and hot phenol (Feramisco et al. 1982) . The Northern blot was performed as described in Sambrook et al. t1989 ). PolylA) + RNA was selected (Promega PolyATtract mRNA isolation system) from 250 ~g of total RNA and run side by side with 15 ~tg of the total sample. Vector templates generating antisense RNA probes for RNase protection were (1) a 750-bp CL8 BamHI fragment cloned into Bluescript KS and linearized at the NcoI site (223 nucleotides with 125 nucleotides protected), and 12) pTRI-[3-actin-mouse plasmid (Ambion, Austin, TX) linearized at the HindIII site (304 nucleotides with 250 nucleotides protected). Labeling, purification, and denaturing gel analysis of riboprobes hybridized at 45°C to 10-20 ~.g of total RNA was performed as described previously {Webb et al. 1991 a).
Antibody production and Western analysis
One milligram of a bacterial fusion protein, from a pGeX-GST construct {Guan and Dixon 1991} which contained 1 kb of Bright amino-terminal coding sequence up to amino acid 346, was purified over glutathione-agarose beads, then emulsed with Cold Spring Harbor Laboratory Press on October 19, 2017 -Published by genesdev.cshlp.org Downloaded from TiterMax (Sigma Chemical Co., St. Louis, MO) and used to immunize a single rabbit. Serum was collected after 1 month that demonstrated a titer of >1:10, 000 on ELISA. Antibodies used for Western analysis were purified by acid elution of serum from a agarose-GST-Bright affinity column. Western blots were performed as described in the Western-Light Chemiluminescent Detection Kit (Tropix Inc., Bedford, MA) except that all solutions were 0.6% EIA grade gelatin (Bio-Rad) and 0.06% Tween 20 (Sigma).
Nuclear matrix isolation, MAR-binding assay, and CASTing
BCg3R nuclear matrix was isolated as described by Webb et al. (1991b) , and for the MAR-binding assay 6 ~.g was washed [50 mM NaC1, 10 mM Tris-HC1 (pH 7.4), 1 mM MgC12, 0.25 M sucrose, 0.25 mg BSA/ml] and bound to 1 ng of 32p-labeled DNA fragment in 50 ~1 of buffer D plus 10 ~g of Escherchia coli DNA and 5 g.g of poly [d(A-T)] for 1 hr at room temperature. The reactions were microcentrifuged for 60 sec to separate the supernatant and matrix fractions, proteinase K digested for 2 hr, phenol-chloroform extracted, and separated on a nondenaturing gel. The CASTing experiments were performed essentially as described by Funk and Wright (1992) . A pool of double-strand 35-mers was created by PCR from a random pool of synthesized 35-base oligonucleotiedes and allowed to bind to in vitro-translated HA-tagged Bright for 20 min in buffer D. HA-tagged Bright was immunoprecipitated as described below and underwent 18 cycles of PCR. These steps were repeated through seven rounds with the addition of 10 ~g of sonicated salmon sperm DNA to the binding reaction. The final reaction was cloned into pBluescript, and plasmids containing inserts were isolated and sequenced.
Imm unoprecipita tions
An HA-tagged version of Bright, containing the 9-amino-acid HA epitope fused in-frame to the amino terminus at amino acid 8, was cotranslated with Bright deletion constructs in the presence of [3SS]methionine. Cotranslate (10 ~1) was added to 1 }zg of protein G--agarose-precipitated anti-HA antibody (Boeringer Mannheim, Indianapolis, IN). The reaction was diluted to 50 gl with buffer D, incubated for 30 min at 4°C, and precipitated. Precipitates were washed twice with both PBS and buffer D (containing 1 mg/ml of BSA and 0.1% NP-40) and separated by protein gel electrophoresis.
Cell culture, transfections, and CAT assays
The CAT expression vectors were constructed by cloning the Ep. and AE~ fragments (described above) into the 5' polylinker of pBL-CAT2 (Luckow and Schutz 1987) . Transfections of cultured cell lines were performed by electroporating 10 ~tg of E~t or AEp. pBL-CAT2, 15 ~g of sense or antisense pBK-CMV Bright, and 10 ~g of a Rous sarcoma virus (RSV)-luciferase plasmid into 2x 10 z cells with a Bio-Rad Gene Pulser set at 960 p.FD and 280 V for M12.4 and J558 cells, 290 V for BW5147 cells, and 300 V for EL4 cells. Fresh medium was added at 24 hr, and transfected cells were lysed by freeze-thaw at 48 hr in 250 mM Tris-HC1 {pH 8.0}. Supernatants were tested for CAT protein using CAT-ELISA (Boehringer Mannheim), and values were normalized for protein concentration and luciferase activity (Optocomp II luminometer, MGS Industries).
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